CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation

Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum‐based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro, in xenografts in vivo, and in primary tumor cells derived from platinum‐treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.

[1]  M. Sonego,et al.  Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells , 2017, Scientific Reports.

[2]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[3]  R. Franco,et al.  Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC , 2016, Oncotarget.

[4]  V. Sexl,et al.  CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation , 2016, Oncogene.

[5]  M. Malumbres,et al.  Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases , 2016, Nature Reviews Molecular Cell Biology.

[6]  M. Sonego,et al.  SUMOylation regulates p27Kip1 stability and localization in response to TGFβ. , 2016, Journal of molecular cell biology.

[7]  A. Vecchione,et al.  p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability , 2015, Proceedings of the National Academy of Sciences.

[8]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[9]  M. Dickler,et al.  The Role of CDK4/6 Inhibition in Breast Cancer. , 2015, The oncologist.

[10]  Evis Sala,et al.  Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis , 2015, PLoS medicine.

[11]  V. Canzonieri,et al.  Genetic characterization of p27kip1 and stathmin in controlling cell proliferation in vivo , 2014, Cell cycle.

[12]  Y. Choi,et al.  Signaling through cyclin D-dependent kinases , 2014, Oncogene.

[13]  N. Manfrini,et al.  Regulation of the DNA damage response by cyclin-dependent kinases. , 2013, Journal of molecular biology.

[14]  L. Zou,et al.  DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.

[15]  M. Malumbres,et al.  A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis , 2013, Cancer cell.

[16]  L. Qin,et al.  Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Croce,et al.  A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis , 2013, Proceedings of the National Academy of Sciences.

[18]  F. Lovat,et al.  Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer , 2013, EMBO molecular medicine.

[19]  E. Oliva,et al.  Precursors and pathogenesis of ovarian carcinoma , 2013, Pathology.

[20]  A. Look,et al.  The requirement for cyclin D function in tumor maintenance. , 2012, Cancer cell.

[21]  A. D. Van den Abbeele,et al.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.

[22]  N. Traficante,et al.  The Australian Ovarian Cancer Study , 2012, Hereditary Cancer in Clinical Practice.

[23]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[24]  S. Gygi,et al.  A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. , 2011, Cancer cell.

[25]  Brian R. Wamhoff,et al.  Chromatin Immunoprecipitation (ChIP): Revisiting the Efficacy of Sample Preparation, Sonication, Quantification of Sheared DNA, and Analysis via PCR , 2011, PloS one.

[26]  M. Malumbres,et al.  Physiological relevance of cell cycle kinases. , 2011, Physiological reviews.

[27]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[28]  V. Velculescu,et al.  Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.

[29]  G. Shapiro,et al.  Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors , 2010, Expert opinion on therapeutic targets.

[30]  Rafael A Irizarry,et al.  Frozen robust multiarray analysis (fRMA). , 2010, Biostatistics.

[31]  F. Lovat,et al.  p27kip1 Controls Cell Morphology and Motility by Regulating Microtubule-Dependent Lipid Raft Recycling , 2010, Molecular and Cellular Biology.

[32]  Li-Huei Tsai,et al.  Cyclin-dependent kinases: a family portrait , 2009, Nature Cell Biology.

[33]  L. Wohlbold,et al.  Behind the wheel and under the hood: functions of cyclin-dependent kinases in response to DNA damage. , 2009, DNA repair.

[34]  C. Peterson,et al.  Chromatin immunoprecipitation (ChIP). , 2009, Cold Spring Harbor protocols.

[35]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[36]  Marco Foiani,et al.  Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.

[37]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[38]  S. Itzkovitz,et al.  Mammalian , 2007 .

[39]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[40]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[41]  Pierre Dubus,et al.  Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.

[42]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[43]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[44]  R. DePinho,et al.  Suppression of Ovarian Follicle Activation in Mice by the Transcription Factor Foxo3a , 2003, Science.

[45]  S. Schreiber,et al.  ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Donahoe,et al.  Müllerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism* , 2000, The Journal of Biological Chemistry.

[47]  G. Viglietto,et al.  Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  G. Viglietto,et al.  Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. , 1999, The Journal of clinical investigation.

[49]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[50]  M. Hung,et al.  Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. , 1993, Cancer research.

[51]  Amina,et al.  Gynecologic oncology , 1990 .

[52]  H. Mackay,et al.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. , 2015, The Lancet. Oncology.

[53]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[54]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[55]  F. Esashi,et al.  Dual role of CDKs in DNA repair: to be, or not to be. , 2009, DNA repair.

[56]  Jiri Bartek,et al.  ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks , 2006, Nature Cell Biology.

[57]  the original work is properly cited. , 2022 .